Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc., a leading player in the pharmaceutical industry, is headquartered in Japan. Established in 1847, the company has made significant strides in the development of transdermal drug delivery systems, particularly through its popular product lines such as Salonpas, which offers pain relief patches. Hisamitsu operates extensively across Asia, Europe, and North America, solidifying its presence in the global market. Renowned for its innovative approach, Hisamitsu focuses on pain management and dermatological products, setting itself apart with unique formulations that enhance patient compliance. The company has achieved notable milestones, including the expansion of its product portfolio and strategic partnerships that bolster its market position. With a commitment to quality and innovation, Hisamitsu continues to be a trusted name in healthcare, dedicated to improving the lives of patients worldwide.
DitchCarbon Score
How does Hisamitsu Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisamitsu Pharmaceutical Co's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hisamitsu Pharmaceutical Co's reported carbon emissions
In 2022, Hisamitsu Pharmaceutical Co., headquartered in Japan, reported total carbon emissions of approximately 69,890,000 kg CO2e for Scope 1, 15,578,000 kg CO2e for Scope 2, and a significant 51,179,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions breakdown includes 5,340,000 kg CO2e from capital goods, 473,000 kg CO2e from business travel, and 25,500,000 kg CO2e from the end-of-life treatment of sold products, among other categories. Comparatively, in 2021, the company recorded 6,923,000 kg CO2e for Scope 1, 15,862,000 kg CO2e for Scope 2, and 48,284,000 kg CO2e for Scope 3 emissions. This indicates a slight increase in Scope 1 and Scope 2 emissions, while Scope 3 emissions also saw an increase, particularly in the capital goods and end-of-life treatment categories. Hisamitsu has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or SBTi commitments. The company’s emissions data is self-reported and does not cascade from a parent organisation, ensuring that the figures reflect its direct operational impact. Overall, while Hisamitsu Pharmaceutical Co. has substantial emissions across all scopes, the lack of formal reduction commitments highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,986,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,919,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 100,228,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hisamitsu Pharmaceutical Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
